Evaluation of the results of complex medical rehabilitation of patients with polyposis rhinosinusitis in the long-term period

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Previous studies on the comparative evaluation of the effectiveness of the course application of therapeutic physical factors during the complex medical rehabilitation of patients with polypous rhinosinusitis showed a rather high efficiency of the additional use of complex physiotherapy (alternating magnetic field and low-intensity laser therapy) in enhancing the regression of the main clinical manifestations of polypous rhinosinusitis and improving the quality of life (QoL) of patients. Considering the chronic and often recurrent nature of polypous rhinosinusitis, along with the relief of the main clinical manifestations of the disease and improvement in the quality of life of patients after treatment, medical rehabilitation of patients should also cover the long-term period.

AIM: Evaluation of the results of complex medical rehabilitation of patients with polyposis rhinosinusitis in the long-term period (after 6, 12 and 18 months) and determination of the optimal time parameters for a repeated course of physiotherapy aimed at maintaining the achieved clinical effect and the level of quality of life of patients.

MATERIALS AND METHODS: The study was performed with the participation of 120 patients with moderate to severe polypous rhinosinusitis and uncontrolled course. All patients were divided into 4 groups by simple fixed randomization. The first group (control, 30 patients) received only basic therapy, including endonasal application of Nasonex 2 doses 2 times a day and daily twice daily lavage of the nasal mucosa. Patients of the second group (comparison group 1, 30 patients) were additionally injected subcutaneously with dupilumab at a dose of 300 μg once every two weeks. In the third group (comparison group 2, 30 patients), against the background of the administration of dupilumab, exposure to an alternating magnetic field was performed. using the apparatus MAGNIT Med TeCo. Patients of the fourth group (main group, 30 patients), in addition to the volume of treatment of patients of the third group, received low-intensity laser radiation of the red spectrum (633 nm) using the AZOR-2K-02 apparatus.

RESULTS: Positive dynamics in terms of assessed clinical indicators throughout the entire observation period was noted only in the comparison groups and the main group. The maximum severity of positive changes was determined in the main group after 6 and 12 months of rehabilitation, exceeding the achieved values in the group with dupilumab. The follow-up period made it possible to establish that 18 months after the start of rehabilitation, there were no significant differences between these groups. The dynamics of the parameters of the microcirculatory tissue system in the comparison groups and the main group in the long-term period indicated the formation of compensatory-adaptive processes aimed at eliminating congestion in the nasal mucosa and associated hypoxia, as well as the normalization of oxygen metabolism and trophism of tissues prone to chronic inflammation.

CONCLUSION: The results obtained convincingly prove the effectiveness of additional course use of an alternating magnetic field in combination with low-intensity laser therapy. The use of this technology, implemented against the background of ongoing biological therapy, shows its increased efficiency up to 12 months after the start of medical rehabilitation. It is advisable to conduct a second course of physiotherapy based on the complex use of an alternating magnetic field and low-intensity laser radiation 9–12 months after the start of medical rehabilitation.

Full Text

Restricted Access

About the authors

Tatyana G. Pelishenko

Clinical hospital 1 of the Department of Presidential Affairs of the Russian Federation

Email: doctor217@mail.ru
ORCID iD: 0000-0001-6597-2167
SPIN-code: 4176-8850

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Larisa S. Kruglova

Central State Medical Academy of Department of Presidential Affairs

Email: kruglovals@mail.ru
ORCID iD: 0000-0002-5044-5265
SPIN-code: 1107-4372

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Sergey N. Nagornev

Central State Medical Academy of Department of Presidential Affairs

Author for correspondence.
Email: drnag@mail.ru
ORCID iD: 0000-0002-1190-1440
SPIN-code: 2099-3854

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Valery V. Boyarintsev

Clinical hospital 1 of the Department of Presidential Affairs of the Russian Federation

Email: wpx@mail.ru
ORCID iD: 0000-0001-9707-3262
SPIN-code: 2491-7199

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

References

  1. Morse JC, Miller C, Senior B. Management of chronic rhinosinusitis with nasal polyposis in the era of biologics. J Asthma Allergy. 2021;14:873–882. doi: 10.2147/JAA.S258438
  2. Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: Rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213–739. doi: 10.1002/alr.22741
  3. Soler ZM, Sauer D, Mace J, et al. Impact of mucosal eosinophilia and nasal polyposis on quality-of-life outcomes after sinus surgery. Otolaryngol Head Neck Surg. 2010;142(1):64–71. doi: 10.1016/j.otohns.2009.10.005
  4. Erskine SE, Hopkins C, Clark A, et al. Chronic rhinosinusitis and mood disturbance. Rhinology. 2017;55(2):113–119. doi: 10.4193/Rhin16.111
  5. Tomoum MO, Klattcromwell C, DelSignore A, et al. Depression and anxiety in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2015;5(8):674–681. doi: 10.1002/alr.21528
  6. Turner JH, Chandra RK, Li P, et al. Identification of clinically relevant chronic rhinosinusitis endotypes using cluster analysis of mucus cytokines. J Allergy Clin Immunol. 2018;141(5):1895–1897.е7. doi: 10.1016/j.jaci.2018.02.002
  7. Lee SE, Hopkins C, Mullol J, et al. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies. Allergy. 2022;77(7):2211–2221. doi: 10.1111/all.15222
  8. Turner JH, Li P, Chandra RK. Mucus T helper 2 biomarkers predict chronic rhinosinusitis disease severity and prior surgical intervention. Int Forum Allergy Rhinol. 2018;8(10):1175–1183. doi: 10.1002/alr.22160
  9. Abramovich SG, Larionova EM. Fundamentals of clinical physiotherapy in otorhinolaryngology. Irkutsk; 2011. 168 p. (In Russ).
  10. Buyavykh AG. Physical therapy in otorhinolaryngological practice. Practical guide. Moscow: Medical Information Agency; 2019. 368 p. (In Russ).
  11. Moskvin SV, Khadartsev AA. Methods of effective laser therapy in the treatment of patients with bronchial asthma (literature review). Bulletin of New Medical Technologies. Electronic edition. 2019;(5):117–148. (In Russ). doi: 10.24411/2075-4094-2019-16522
  12. Moskvin SV. Fundamentals of laser therapy. Series "Effective laser therapy". Vol. 1. Moscow-Tver: Triada; 2016. 896 p. (In Russ).
  13. Ivanov DV, Tokareva SV. Selected issues of magnetotherapy (a brief review of the literature). Bulletin of New Medical Technologies. Electronic edition. 2021;15(4):94–102. (In Russ). doi: 10.24412/2075-4094-2021-4-3-4
  14. Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl. 29):1–464. doi: 10.4193/Rhin20.600
  15. Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2021;147(1):29–36. doi: 10.1016/j.jaci.2020.11.013
  16. Gorbunov SA, Rusetsky YuYu, Kudryashov SE, et al. Review of international questionnaires and questionnaires for assessing the quality of life in acute and chronic rhinosinusitis. Russian Rhinology. 2021;29(2):97–106. (In Russ). doi: 10.17116/rosrino20212902197
  17. Braid J, Islam L, Gugiu C, et al. Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps. World Allergy Organ J. 2023;16(5):100776. doi: 10.1016/j.waojou.2023.100776
  18. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: Developing guidance for clinical trials. J Allergy Clin Immunol. 2006;118(5 Suppl):S17–61. doi: 10.1016/j.jaci.2006.09.005
  19. Beresten NF, Sandrikov VA, Fedorova SI, eds. Functional diagnostics. National leadership. Moscow: GEOTAR-Media; 2022. 784 р. (In Russ).
  20. Ponomarenko GN. Topical issues of physiotherapy. Selected lectures. Saint Petersburg: Military Medical Academy; 2010. Р. 112–135. (In Russ).
  21. Benkov AA, Nagornev SN, Frolkov VK, et al. Evaluation of nonspecific mechanisms of effectiveness of course combined use of low-frequency electrostatic field and transcranial magnetotherapy in patients with metabolic syndrome. Kurortnaya meditsina. 2022;(2):12–23. (In Russ). doi: 10.51871/2304-0343_2022_2_12
  22. Rubinsky AV, Linkova NS, Chalisova NI, et al. Epigenetic regulation of adaptogenesis in pathology and aging. Uspekhi gerontologii. 2021;34(1):10–17. (In Russ). doi: 10.34922/AE.2021.34.1.001
  23. McGee SL, Hargreaves M. Epigenetics and exercise. Trends Endocrinol Metab. 2019;30(9):636–645. doi: 10.1016/j.tem.2019.06.002
  24. Fenixova LV, Gurina OYu. Ultrastructural changes in microhemodynamics in conditions of chronic inflammation of the mucous membrane of the paranasal sinuses. Detskaya bol'nitsa. 2013;(3):40–42. (In Russ).
  25. Fokkens W, van Der Lans R, Reitsma S. Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis. Expert Opin Biol Ther. 2021;21(5):575–585. doi: 10.1080/14712598.2021.1901881
  26. Fujieda S, Matsune S, Takeno S, et al. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status. Allergy. 2022;77(1):186–196. doi: 10.1111/all.14906

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86508 от 11.12.2023
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80650 от 15.03.2021
г.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies